Cargando…

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed

Conventional chemotherapy for lung cancer exerts anti-tumor effects through cytotoxicity, and through immunologic regulation by reducing specific T cell subsets and inducing the expression of programmed death ligand 1 (PD-L1) on tumor cells. Even though pemetrexed has shown huge potential in combina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Pei, Bao, Zhang, Xu, Liming, Zhou, Jianya, Lu, Guohua, Yao, Yinan, Liu, Rong, Gao, Qiqi, Shen, Yihong, Zhou, Jianying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630412/ https://www.ncbi.nlm.nih.gov/pubmed/29029512 http://dx.doi.org/10.18632/oncotarget.19973

Ejemplares similares

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement
por: Zhou, Jianya, et al.
Publicado: (2015)

IL-17A-producing T cells are associated with the progression of lung adenocarcinoma
por: Bao, Zhang, et al.
Publicado: (2016)

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
por: Schmidt, Lars Henning, et al.
Publicado: (2015)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

Loss of LIMCH1 predicts poor prognosis in patients with surgically resected Lung Adenocarcinoma: A study based on Immunohistochemical Analysis and Bioinformatics
por: Cao, He, et al.
Publicado: (2021)

Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
por: Jung, Minkyu, et al.
Publicado: (2013)

PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy
por: Qin, Yi, et al.
Publicado: (2020)

Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients
por: Zhou, Xueheng, et al.
Publicado: (2019)

Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell
por: Zhao, Jing, et al.
Publicado: (2016)

Comparison of ALK status between primary and corresponding lymph node metastatic tumors in lung cancer patients
por: Gao, Qiqi, et al.
Publicado: (2017)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Significant Radiologic Response of Pancreatic Metastasis After Targeted Therapy of Ceritinib (LDK378) for ALK-Rearranged Lung Adenocarcinoma Presenting With Hyperglycemia
por: Zheng, Jing, et al.
Publicado: (2017)

PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer
por: Wu, Yanhua, et al.
Publicado: (2017)

Blood T cell diversity associated with the prognosis of advanced non‐small cell lung carcinoma treated with first‐line pemetrexed based chemotherapy
por: Qian, Li, et al.
Publicado: (2021)

Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma
por: Zhou, Xincheng, et al.
Publicado: (2022)

Deguelin Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells through Regulating the Expression of Galectin-1
por: Yan, Bing, et al.
Publicado: (2016)

Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma
por: YANG, MIN, et al.
Publicado: (2014)

Menopausal Symptoms among Breast Cancer Patients: A Potential Indicator of Favorable Prognosis
por: Chen, Yong, et al.
Publicado: (2013)

Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis
por: Zhang, Guoqiao, et al.
Publicado: (2019)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

Deguelin Attenuates Allergic Airway Inflammation via Inhibition of NF-κb Pathway in Mice
por: Bao, Zhang, et al.
Publicado: (2017)

BTN3A2 Expression Is Connected With Favorable Prognosis and High Infiltrating Immune in Lung Adenocarcinoma
por: Lin, Yuansheng, et al.
Publicado: (2022)

The lncRNA ENSG00000254041.1 promotes cell invasiveness and associates with poor prognosis of pancreatic ductal adenocarcinoma
por: Chen, Bo, et al.
Publicado: (2020)

Decitabine Sensitizes the Radioresistant Lung Adenocarcinoma to Pemetrexed Through Upregulation of Folate Receptor Alpha
por: Wang, Yuqing, et al.
Publicado: (2021)

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
por: Guo, Long-Hua, et al.
Publicado: (2020)

High Rab27A expression indicates favorable prognosis in CRC
por: Shi, Chuanbing, et al.
Publicado: (2015)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy
por: MOU, WENJUN, et al.
Publicado: (2014)

Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1
por: Liu, Liang, et al.
Publicado: (2018)

A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features
por: Zhou, Jianya, et al.
Publicado: (2016)

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
por: Cui, Jiadong, et al.
Publicado: (2018)

Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer
por: Li, Che-Hsing, et al.
Publicado: (2021)

Dysregulated ferroptosis‐related genes indicate potential clinical benefits for anti–PD‐1/PD‐L1 immunotherapy in lung adenocarcinoma
por: Zhou, Min, et al.
Publicado: (2021)

Nephrotoxicity in a Patient Treated with Pemetrexed
por: Zajjari, Y., et al.
Publicado: (2017)

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Song, Yipeng, et al.
Publicado: (2021)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Epigenetic Age Acceleration of Stomach Adenocarcinoma Associated With Tumor Stemness Features, Immunoactivation, and Favorable Prognosis
por: Hong, Chunhong, et al.
Publicado: (2021)

Deguelin Attenuates Non-Small-Cell Lung Cancer Cell Metastasis by Upregulating PTEN/KLF4/EMT Signaling Pathway
por: Lu, Guohua, et al.
Publicado: (2022)

VISTA is associated with immune infiltration and predicts favorable prognosis in TNBC
por: Zhang, Mi, et al.
Publicado: (2022)

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma
por: Ke, Yuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8pp7mqgko5g9oircdj7smkf6tn